Pathophysiology of typical hemolytic uremic syndrome

Diana Karpman, MD, PhD[1*], Lisa Sartz; MD[1], Sally Johnson, MB ChB, PhD[2]

1. Department of Pediatrics, Clinical Sciences Lund, Lund University, Lund, Sweden
2. Department of Paediatric Nephrology, Birmingham Children's Hospital, Steelhouse Lane, Birmingham, B4 6NH, UK

* Corresponding author: Professor Diana Karpman

email: diana.karpman@med.lu.se

Telephone: +46-46-2220747

Fax: +46-46-2220748

ABSTRACT

The typical form of hemolytic uremic syndrome (HUS) is associated with Enterohemorrhagic *Escherichia coli* (EHEC) infection. The disease process is initiated and perpetuated by interactions between the pathogen, its virulence factors and host cells as well as the host response. During EHEC-associated HUS, alterations occurring at the intestinal mucosal barrier and in the circulation, as well as on endothelial cells and other target-organ cells, lead to cell activation and/or cytotoxicity, and trigger a pro-thrombotic state. This review summarizes current knowledge regarding the interactions of the pathogen and its virulence factors with cells in the intestine, bloodstream, kidney and brain. Mechanisms of bacterial colonization, toxin circulation and induction of target organ damage are discussed.

Key words

Hemolytic uremic syndrome, Shiga toxin, enterohemorrhagic *Escherichia coli*, thrombotic microangiopathy, kidney

INTRODUCTION

Hemolytic uremic syndrome (HUS) is diagnosed when the simultaneous features of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure are present. Whilst HUS has a number of underlying etiologies, over 90% of cases in developed countries follow gastrointestinal infection with Enterohemorrhagic *Escherichia coli* (EHEC).[1] This review summarizes current concepts of the pathogenesis of EHEC-associated HUS, or so-called "typical HUS".

EPIDEMIOLOGY

The incidence of EHEC-associated HUS peaks in children under 5 years old, and rises again in the elderly [1]. The incidence rate of EHEC-associated HUS is similar in Europe, North America and Australia,[1,2] but 7-10 times higher in Argentina.[3] EHEC colonize animals, primarily cattle, without causing disease.[4] Transmission to humans occurs by consumption of contaminated meat, milk products, water, fruit and vegetables.[5] Direct contact with animals during visits to farms is increasingly recognized as a risk factor.[6] Approximately 10% of children exposed to EHEC infection develop diarrhea (usually bloody), and 15% of children with diarrhea will develop HUS. The incubation period is usually less than a week, and the interval between onset of diarrhea and diagnosis of HUS is approximately 6-7 days.[7,8]

HISTOLOGY

HUS is characterized by widespread thrombotic microangiopathy (TMA) in renal glomeruli, the gastrointestinal tract, brain and the pancreas.[9] TMA defines a lesion of vessel wall thickening, usually at the arteriolar-capillary junction, with swelling or detachment of the

endothelial cell from the basement membrane, accumulation of amorphous material in the subendothelial space, intraluminal thrombosis and partial or complete obstruction of the vessel lumen.[9] This suggests that microvascular endothelial cell injury is central to the pathogenesis of HUS. In addition, arteriolar thromboses are common at the hilum of glomeruli and are also seen proximally in interlobular arteries. In severe cases, cortical necrosis may be present.[10]

EHEC VIRULENCE FACTORS

EHEC cause a range of clinical manifestations, including diarrhea, hemorrhagic colitis and HUS. HUS is predominantly associated with serotype O157:H7, although other serotypes, including O26:H11, O103:H2, O111:NM, O121:H19, and O145:NM have been reported.[5] EHEC possess certain virulence factors that contribute to the development of HUS. These factors include proteins that promote intestinal colonization and toxins that disseminate within the host resulting in microvascular injury.

The virulence factors that promote intestinal colonization of EHEC are contained within horizontally acquired gene cassettes known as pathogenicity islands (PAI). One such PAI is the locus of enterocyte effacement (LEE),[11] which allows EHEC to attach to the luminal surface of host enterocytes and to cause effacement of the microvilli, resulting in watery diarrhea through loss of absorptive surface. The LEE encodes the adhesin intimin, a type three secretion system (TTSS) and secreted proteins. The TTSS translocates bacterial proteins from EHEC directly into host enterocytes, affecting cellular structure and function.[11,12]

Shiga toxin

Shiga toxin (Stx) is considered the most important factor for the virulence of EHEC. Stx consists of a single enzymatically active A-subunit linked to five B-subunits. EHEC may secrete a number of distinct Stxs (Stx1 and Stx2 and a number of subtypes). Each Stx is encoded by a specific bacteriophage, and EHEC strains with more than one bacteriophage can produce more than one toxin.[13] EHEC responsible for HUS express Stx2 more often than Stx1.[14] Bacteriophages can be induced either spontaneously,[15] or by certain antibiotics, including quinolones,[16] increasing the level of Stx production, which might be an important factor for the pathogenicity of EHEC. The toxin is produced by *Shigella dysenteriae* 1 as well as by EHEC. Stx produced by *Shigella* is almost homologous to Stx1 produced by EHEC.

The glycosphingolipid receptor for Stx is globotriaosylceramide (Gb3). The distribution of Gb3 has been found to determine the localization of pathological lesions in HUS in humans and other animals (glomerular endothelium, brain, pancreas).[17] Bacteremia is rarely reported in HUS and so it is likely that Stx is transported from the intestine to distant sites. Most studies of the interaction of Stx with human cells have been carried out on endothelial cells. After binding of Stx to Gb3 on endothelial cells, Stx is internalized by receptor-mediated endocytosis. Inside the host cell, the A subunit is proteolytically cleaved to an enzymatically active fragment, which cleaves a residue within the 60S ribosomal subunit. This inhibits protein synthesis, causing cell death.[18] In addition to cytotoxicity, Stx may also exert activating effects on endothelial cells, for example stimulation of interleukin-8 (IL-8) and monocyte chemoattractant protein-1 production and upregulation of adhesion molecule expression.[19] Human umbilical vein endothelial cells (HUVEC) exposed to Stx show an upregulation of genes encoding cytokines, cellular adhesion molecules and transcription

factors.[20] Endothelin-1 is a potent vasoconstrictor produced by endothelial cells. Stx causes upregulation of endothelin-1 (ET-1) mRNA and protein levels.[21] Furthermore, Stx promotes leukocyte dependent inflammation[22] and endothelial cell activation, with a change to a more procoagulant endothelial cell phenotype, in addition to endothelial cell damage[23] which will trigger platelet adhesion to the subendothelium.

Other virulence factors

Since HUS can develop after infection with EHEC strains which do not produce Stx,[24] it is likely that even other virulence factors may play a role in the pathogenesis of HUS. Cytolethal distending toxin V (CDT-V), EHEC hemolysin (EHEC-hly), and subtilase cytotoxin are potential candidates.[25]

Cytolethal distending toxin

About 5% of EHEC 0157:H7 strains investigated carry a gene encoding CDT-V,[26] the cytolethal distending toxin. CDT-V is a cyclomodulin that causes cell cycle arrest.[25] CDT-V may contribute to endothelial injury by causing irreversible G2/M cell cycle arrest, growth inhibition and death of human endothelial cells.[27]

EHEC hemolysin

EHEC-hly is a pore-forming cytolysin encoded on a large 60 MD plasmid and released from EHEC strains associated with HUS. Aldick et al identified Stx gene-negative EHEC O26 strains as the only pathogens in the stools of five patients with HUS and examined the strains

for potential virulence factors and interactions with microvascular endothelial cells.[28] All five isolates possessed the gene encoding EHEC-hly and were cytotoxic to human brain microvascular endothelial cells. Toxicity was significantly reduced in an EHEC-hly-negative strain, and reproduced by introducing recombinant EHEC-hly to EHEC O26, suggesting that EHEC-hly may have cytotoxic properties.

Subtilase cytotoxin

In addition to Stx, a subset of EHEC strains secrete another extremely lethal cytotoxin termed subtilase (SubAB).[29] This toxin is lethal in mice, inducing thrombosis and necrosis in multiple organs, thus mimicking the clinical presentation of HUS. Its mechanism of action is inactivation of the endoplasmic reticulum chaperone BiP (immunoglobulin heavy chain–binding protein) by the serine protease activity of its A subunit.[30] A recent study showed that SubAB prevents secretion of immunoglobulins from B lymphocytes.[31]

PATHOGENESIS OF EHEC-INDUCED DISEASE

EHEC is a non-invasive pathogen.[32,33] Bacterial virulence factors gain access to the circulation after causing intestinal damage, and thereby reach the target organ. In the following section we will review the influence of the intestinal microflora and the host hormonal response on EHEC motility, colonization and Stx production. Intestinal colonization triggers a local inflammatory and innate immune response. Stx and lipopolysaccharide (LPS) are released into the circulation and bind to blood cells thus reaching the renal microcirculation. The consequences of Stx and LPS release into the

circulation, including their interactions with blood cells and endothelium, result in a prothrombotic state within the microvasculature.

EHEC in the intestine

Very few EHEC colony-forming units are capable of inducing clinical symptoms.[33] The mechanisms by which colonization and expression of virulence factors occur in the intestine have been extensively studied. After ingestion, EHEC reaches the ileum and was detected in the ileocecal valve in one patient sample.[34] EHEC is assumed to initially bind to villi of the terminal ileum and follicle-associated epithelium of Peyer's patches[35,36] followed by colonization of the colon. Cross-talk occurs between EHEC and the commensal intestinal microflora during colonization. EHEC also interact with the host hormonal response. This results in activation of virulence factors, such as those encoded in the LEE,[37] responsible for formation of the attaching and effacing lesion enabling intimate attachment to the intestinal cell, the expression of flagella thereby enhancing mobility, and the induction of Stx.[38,39] These interactions involve bacterial sensing of a molecule termed auto-inducer-3, produced by the intestinal microflora, as well as a response to the host stress hormones epinephrine and norepinephrine, involving the bacterial membrane histidine sensor kinases QseC and QseE. The recent description of the QseC signaling cascade[38] revealed that bacteriaare responsive to host adrenergic signals and this phenomenon would most probably be increased during hemorrhagic colitis as more catecholamines are released from the bloodstream into the intestine.

EHEC strains that lack the LEE pathogenicity island-encoded TTSS and its effector proteins are also capable of colonization and induction of disease in humans.[40] EHEC possess non-

LEE proteins promoting adhesion and virulence.[41-44] For example, the expression of the non-LEE EspI/NleA effector protein by EHEC has been associated with severe disease.[43]

Stx is causally related to severe EHEC-associated disease and the induction of HUS. In a primate model of Shigellosis, the toxin induced dysentery.[45] Enterocytes do not express the Gb3 receptor to which the toxin binds but Stx1 and Stx2 were shown to bind to Gb3-expressing intestinal Paneth cells.[46] Even though intestinal epithelial cells do not express Gb3 they may take up the toxin by actin-dependent macropinocytosis.[34] Stx causes apoptosis of intestinal epithelial cells *in vitro* in human[47,48] and mouse intestinal cells[49] and may translocate across polarized intestinal epithelial cells using a transcellular route,[50] an effect enhanced by neutrophil migration in the opposite direction.[51] Recent studies have shown that Stx production can be induced by quorum sensing signaling[39] but also suppressed by the normal human intestinal microflora.[52] There are several variants of Stx2,[25] some of which exhibit increased virulence to man such as Stx2c and Stx2d(activatable). The latter is activated by intestinal mucus and elastase, is present in EHEC strains that lack the LEE and has been associated with severe disease.[53] It has been assumed that after damaging the mucosal epithelium, Stx may gain access to, and damage, the intestinal vasculature.[54]

EHEC may also secrete SubAB in the intestine. SubAB recognizes a monosaccharide, terminating with the sialic acid N-glycolylneuraminic acid (Neu5Gc), as its receptor on human endothelial cells and intestinal epithelial cells.[55] This glycan is not synthesized in humans but provided in the human diet, specifically in food which may be contaminated with EHEC, such as red meat and milk products,[56] enabling SubAB to cause intestinal damage even in the absence of an inherent receptor.

EHEC infection induces intestinal inflammation, cell death by apoptosis and necrosis as well as an inflammatory response. Stx upregulates the proinflammatory cytokine IL-8, as well as other C-X-C chemokines in the gut.[57-59] Triggering an inflammatory response in the intestine and systemically may upregulate the Stx receptor on endothelial cells.[60] EHEC LPS may also play a role in inducing a mucosal immune response during the initial phase of disease[61,62] which may promote bacterial clearance. A reduced initial response was shown to increase the bacterial burden in mice, allowing more severe disease to proceed both locally and systemically, presumably due to increased secretion of Stx.[62] A recent study reported that EHEC could suppress the intestinal epithelial cytokine response to Stx,[59] an effect that could facilitate bacterial colonization. Host anti-microbial peptides may also be involved in the initial defense against intestinal infection, protecting the mucosal surface from colonization. This has been documented for *Citrobacter rodentium,*[63] a pathogen causing similar attaching and effacing lesions in the gut, and suggested as a plausible protective mechanism in EHEC infection as well.

EHEC virulence factors and blood cells

Damage to the intestinal epithelium allows bacterial virulence factors to enter the circulation. Blood cells from patients with HUS are coated with Stx and LPS.[64,65] During HUS, Stx circulates bound to platelets, monocytes and neutrophils as well as to platelet-monocytes and platelet-neutrophils in complex.[64,66] Stx may bind to blood cells via the Gb3 receptor as well as other glycolipid receptors.[67-69] LPS binds to blood cells via Toll-like receptor 4, which, on platelets, is in complex with CD62 (P-selectin).[65]

Stx induces cell death by blocking protein synthesis[70] or by apoptosis.[54] Neutrophils, monocytes and IgM-producing B lymphocytes exhibit resistance to Stx's cytotoxic effect.[69,71-73] In macrophage-like THP-1 cells, both apoptotic and cell survival signaling pathways were activated after exposure to Stx1.[74] Thus, most leukocytes encountering Stx will not undergo cell death, allowing the toxin to circulate bound to their cell membrane.

Leukocytosis and high IL-8 levels at HUS presentation are associated with poor outcome.[75,76] Neutrophils demonstrate prolonged survival during severe forms of HUS.[77] Interestingly, Stx has been shown to prolong the life-span of neutrophils,[71] and impair neutrophil migration in mice.[78] *E. coli* O157 also secrete StcE, a protease shown to increase the neutrophil oxidative burst and adhesion, thus impairing neutrophil migration[79] which could explain increased tissue destruction at sites of neutrophil influx in HUS patients.[80] Neutrophil activation during HUS and in experimental models was recently reviewed.[81]

The role of monocytes during HUS may be related to toxin transport[64,82] although the transfer of Stx from monocytes to its target cells has not been conclusively documented. The toxin is, however, capable of stimulating the human monocytic cell line THP-1 to secrete cytokines.[69,83] Guessous et al showed that THP-1 cells stimulated with Stx2 released the chemokines IL-8, macrophage-derived chemokine (MDC), and Regulated on Activation, Normal T-cell Expressed and Secreted (RANTES) and this effect was enhanced in the presence of LPS.[84] The released chemokines activated platelets, indicating an interaction between these blood cells. Stimulation of THP-1 cells with Stx1 also led to upregulation of tissue factor.[85] We have recently shown that monocytic microparticles bearing tissue factor

are released during HUS and these microparticles may contribute to the prothrombotic state[64] as described below.

During HUS, platelets are deposited on injured endothelial cells. Multiple microthrombi lead to thrombocytopenia. Many studies have addressed the pro-thrombotic state occurring during EHEC infection and resulting in TMA (reviewed in[86]). Platelets are activated by a direct interaction with LPS, Stx,[65,87,88] chemokines[84] and by factors released from damaged endothelium. Coagulation factors are, however, not consumed during this process. Mice inoculated with *E. coli* O157:H7 developed thrombocytopenia.[62] Likewise, mice treated with Stx2 and LPS developed thrombocytopenia and platelet clumping in the kidneys.[89]

During the acute phase of HUS, patients were shown to have elevated levels of tissue factor,[90] circulating tissue factor-bearing platelet-monocyte complexes as well as tissue factor-expressing microparticles, mainly derived from platelets, but also from monocytes.[64] These tissue factor expressing-complexes and microparticles decreased considerably after the patients' recovery. Stimulation of whole blood with Stx2 induced the formation of platelet-monocyte complexes, and, to a lesser degree, platelet-neutrophil complexes. The effect was enhanced when blood cells were co-stimulated with Stx2 and LPS, and O157LPS was more potent than other LPS serogroups. The formation of platelet-leukocyte complexes was further enhanced by application of high shear stress, mimicking the capillary shear stress present in glomeruli.[64]

In addition to its effect on platelets and monocytes, Stx induces tissue factor expression on endothelial cells.[91-93] Tissue factor is the receptor for coagulation factor VII, thus converting factor X to Xa in the extrinsic pathway. Tissue factor expression will trigger thrombin generation resulting in clot formation and further platelet activation. Thrombin's role in TMA was implied by its increased generation in mice injected with Stx2 and LPS[94] as well as by the inhibitory effect of lepirudin, a thrombin inhibitor, on Stx-mediated injury in the dog.[95]

The mechanism by which hemolysis occurs during HUS has not been elucidated. Red blood cell fragmentation is noted and has been mimicked in animal models of EHEC infection using the whole bacterium[61] or Stx alone.[95,96] It has been assumed that fragmentation is the result of mechanical breakdown in occluded vessels but oxidative damage has also been proposed as a mechanism of hemolysis.[97] Regardless of the cause, the products of hemolysis may have a cytotoxic effect. Bitzan et al showed that heme and Stx induced an additive cytotoxic effect on renal tubular epithelial cells and microvascular endothelial cells.[98]

Renal damage in HUS

The main target organ affected during HUS is the kidney, and in severe cases also the brain, as well as other organs.[99] Stx, with or without LPS, has been studied as the major virulence factor affecting target organs. In order to exert its cytotoxic effect, the toxin binds to its receptor, and kidney cell vulnerability is predicted by the presence of the Gb3 receptor.[23,100-102] Human kidneys exhibit both glomerular and tubular damage during HUS with extensive apoptosis of renal cortical cells.[103,104] It is, however, unclear if the initial toxin insult occurs at the glomerular or tubular cell level.

Stx exerts a cytotoxic and apoptotic effect on glomerular endothelial[105,106] and epithelial cells.[107,108] The cytotoxic effect is enhanced in the presence of TNF-α[60] as well as IL-1, LPS and butyrate.[108] Stx1 was shown to upregulate cytokine production in glomerular epithelial cells[109] and tubular epithelial cells,[110] which would in turn enhance toxicity. Furthermore, Stx induced expression of the chemokine fractalkine on glomerular endothelial cells promoting leukocyte adhesion to the endothelium,[111] an effect verified *in vivo* in mice and suggested to contribute to severity of disease in humans.[112]

Studies have demonstrated that tubular cells are affected during HUS.[103] Tubular cell damage was indicated by an increase of neutrophil gelatinase-associated lipocalcin in patient urine.[113] The beneficial effect of intravenous volume expansion during the early stages of disease[114] could also indicate an initial reversible tubular cell injury. EHEC infection in mice and rats induced acute tubular injury[103,115 62,116] and Stx, in particular, triggered tubular cell apoptosis in mice,[103] affecting primarily the cortical tubular cells. Silberstein et al showed that Stx2 could inhibit water absorption in primary human proximal tubular cells[117] and others have shown increased urine volume in vivo in rats[116,118] and mice[119] attributed to collecting duct injury. Thus both proximal tubular as well as collecting duct cells appear to be vulnerable to Stx. Interestingly, human proximal tubular cells exposed to Stx1 exhibited increased tissue factor expression[120] suggesting that these cells may trigger the coagulation system upon Stx stimulation. Tissue factor is expressed in glomerular capillary endothelial cells and tubular epithelial cells during EHEC-associated HUS (Figure 1).

Podocytes are highly specialized glomerular epithelial cells. Using murine podocytes Morigi et al showed that Stx2 increased endothelin-1 mRNA and protein expression affecting cytoskeleton remodeling.[121] A similar affect of Stx1 and Stx2 on preproendothelin-1 expression was previously reported in vascular endothelial cells.[122] Thus, by affecting endothelin-1 expression, Stx will possibly modulate vascular tone and glomerular permeability.

Mesangial expansion, necrosis and mesangiolysis have been described in renal samples obtained during HUS although some of the cases reported were presumably not EHEC-associated.[123] Mesangial cells also possess Gb3 receptors which are upregulated by TNF-α[124] enabling Stx to inhibit protein synthesis and exert a cytotoxic effect, after prolonged incubation,[107,125] as well as reduce nitric oxide production.[126] Stx did not, however, stimulate the release of cytokines or chemokines from mesangial cells.[127]

Brain damage in HUS

A subset of HUS patients will develop central nervous system involvement. Symptoms may vary from mild irritability to coma. Human brain expresses the Gb3 receptor in neurons and endothelium.[128] *In vitro* experiments have shown that human brain microvascular endothelial cells undergo apoptosis after exposure to Stx2;[129] the effect was enhanced by TNF-α which sensitized cells to Stx1-induced apoptosis.[130] This is due to upregulation of the Gb3 receptor.[131] In the mouse Gb3 was demonstrated in CNS neurons.[128] Mice injected with Stx develop convulsions with brain edema[101] and hind-limb paralysis.[128] Gb3-null mutant mice were protected[101] indicating the importance of Gb3 expression for targeting of Stx-induced damage. Intracerebroventricular injection of Stx2 in rats led to neuron apoptosis and glial

affection with reactive astrocytes.[132,133] Of note, stimulation of human brain endothelial cells with Stx1 and TNF-α was cytotoxic but also induced cytokine synthesis and release.[134] The cellular signaling events that dictate if the toxin will induce a cytotoxic or stimulatory response are yet to be elucidated.

The emerging role of complement

Of those cases of HUS not associated with EHEC infection, inherited disorders of complement regulation are the most frequent underlying cause.[8] In these cases of atypical HUS, TMA is thought to result from complement-mediated endothelial damage and platelet activation.[135,136] Limited evidence suggests that complement activation may play a role in the pathogenesis of EHEC-associated HUS. Patients with EHEC-associated HUS had elevated levels of complement factors Bb and sC5b-9 at presentation, indicating activation of complement through the alternative pathway.[137] Stx activates complement in human serum via the alternative pathway.[138] In addition, Stx binds to the cell binding domains of complement factor H, and appears to inhibit the regulatory function of factor H on cell surfaces.[138] Complement activation may be a secondary phenomenon, which could, nonetheless, exacerbate renal injury.

The chain of events from EHEC ingestion to the development of HUS

EHEC will, after ingestion, colonize the terminal ileum and follicle-associated epithelium of Peyer's patches.[35] In the gut the bacterial virulence and adhesion will be activated by interkingdom signaling,[139] allowing colonization to proceed with release of virulence factors such as Stx and LPS. It is, as yet, unclear which host factors increase susceptibility to develop HUS. Bacterial virulence factors migrate across the intestinal epithelium,[51] gain access to the

blood, circulating bound to platelets, monocytes and neutrophils as well as platelet-leukocyte aggregates.[64] Hypothetically, larger amounts of circulating Stx and LPS could increase the risk to will develop HUS. In line with this assumption, and using a limited number of patient samples, Ståhl et al showed that during EHEC infection, only the platelets of patients who later developed HUS carried Stx and LPS on their surface.[65] Thrombin generation and fibrinolysis inhibition also precede the development of HUS.[140]

Stx exerts a stimulatory effect on cells, triggering cytokine release and/or tissue factor expression, as well as a cytotoxic effect inhibiting protein synthesis and inducing apoptosis. These effects may occur in the circulation, affecting blood cells, as well as when reaching Gb3-expressing target cells in the kidney, brain and other organs. In the presence of high shear, as in the renal glomerular microcirculation, the effects of Stx and LPS may be enhanced,[22,64] resulting in leukocyte adhesion and the formation of microthrombi.

CONCLUSION

This review has summarized many of the known mechanisms by which EHEC colonize the intestine and induce disease affecting the intestine, kidney and brain, as well as other organs, in infected individuals. As EHEC is a non-invasive organism the bacteria triggers lesions in the host by the interaction of its factors with host cells, firstly at the mucosal level, followed by binding to blood cells and transfer to target organs. Ultimately this will lead to endothelial cell injury and platelet activation resulting in a prothrombotic state. Advances in understanding the complex events leading to EHEC-induced thrombotic microangiopathy will hopefully facilitate the development of specific therapeutics agents in the future.

Acknowledgments

Diana Karpman is supported by grants from The Swedish Research Council (K2010-65X-14008-10-3), The Torsten and Ragnar Söderberg Foundation, Konung Gustav Vs 80-årsfond, Crown Princess Lovisa's Society for Child Care, Fanny Ekdahl foundation and is the recipient of a clinical-experimental research fellowship from the Royal Swedish Academy of Sciences. Lisa Sartz is supported a grant from the Queen Silvia Jubilee Fund.

References

1. Lynn RM, O'Brien SJ, Taylor CM, et al. Childhood hemolytic uremic syndrome, United Kingdom and Ireland. Emerg Infect Dis 2005;11:590-596
2. Loirat C, Marczak E. Haemolytic Uraemic Syndrome. In: Cochat P ed, European Society for Paediatric Nephrology Handbook. Lyon: Medcom; 2002:337-342
3. Lopez EL, Contrini MM, Devoto S, et al. Incomplete hemolytic-uremic syndrome in Argentinean children with bloody diarrhea. J Pediatr 1995;127:364-367
4. Borczyk AA, Karmali MA, Lior H, Duncan LMC. Bovine reservoir for verotoxin-producing Escherichia coli 0157:H7. Lancet 1987;329:98-98
5. Karmali MA. Host and pathogen determinants of verocytotoxin-producing Escherichia coli-associated hemolytic uremic syndrome. Kidney Int 2009:S4-7
6. Goode B, O'Reilly C, Dunn J, et al. Outbreak of Escherichia coli O157: H7 Infections After Petting Zoo Visits, North Carolina State Fair, October-November 2004. Arch Pediatr Adolesc Med 2009;163:42-48
7. Milford DV, Taylor CM, Guttridge B, et al. Haemolytic uraemic syndromes in the British Isles 1985-8: association with verocytotoxin producing Escherichia coli. Part 1: Clinical and epidemiological aspects. Arch Dis Child 1990;65:716-721
8. Johnson S, Taylor C. What's new in haemolytic uraemic syndrome? Eur J Ped 2008;167:965-971
9. Ruggenenti P, Noris M, Remuzzi G. Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int 2001;60:831-846
10. Gagnadoux MF, Habib R, Gubler MC, Bacri JL, Broyer M. Long-term (15-25 years) outcome of childhood hemolytic-uremic syndrome. Clin Nephrol 1996;46:39-41
11. Dean P, Kenny B. The effector repertoire of enteropathogenic E. coli: ganging up on the host cell. Curr Op Microbiol 2009;12:101-109

12. Delahay RM, Frankel G, Knutton S. Intimate interactions of enteropathogenic Escherichia coli at the host cell surface. Curr Op Infect Dis 2001;14:559-565

13. Furst S, Scheef J, Bielaszewska M, et al. Identification and characterisation of Escherichia coli strains of O157 and non-O157 serogroups containing three distinct Shiga toxin genes. J Med Microbiol 2000;49:383-386

14. Boerlin P, McEwen SA, Boerlin-Petzold F, et al. Associations between virulence factors of Shiga toxin-producing Escherichia coli and disease in humans. J Clin Microbiol 1999;37:497-503

15. Shimizu T, Ohta Y, Noda M. Shiga toxin 2 is specifically released from bacterial cells by two different mechanisms. Infect Immun 2009;77:2813-2823

16. Zhang X, McDaniel AD, Wolf LE, et al. Quinolone antibiotics induce Shiga toxin-encoding bacteriophages, toxin production, and death in mice. J Infect Dis 2000;181:664-670

17. Zoja C, Corna D, Farina C, et al. Verotoxin glycolipid receptors determine the localization of microangiopathic process in rabbits given verotoxin-1. J Lab Clin Med 1992;120:229-238

18. Obrig TG, Moran TP, Brown JE. The mode of action of Shiga toxin on peptide elongation of eukaryotic protein synthesis. Biochem J 1987;244:287-294.

19. Zoja C, Angioletti S, Donadelli R, et al. Shiga toxin-2 triggers endothelial leukocyte adhesion and transmigration via NF-kappaB dependent up-regulation of IL-8 and MCP-1. Kidney Int 2002;62:846-856.

20. Matussek A, Lauber J, Bergau A, et al. Molecular and functional analysis of Shiga toxin-induced response patterns in human vascular endothelial cells. Blood 2003;102:1323-1332

21. Petruzziello TN, Mawji IA, Khan M, Marsden PA. Verotoxin biology: molecular events in vascular endothelial injury. Kidney Int;75:S17-S19

22. Zoja C, Angioletti S, Donadelli R, et al. Shiga toxin-2 triggers endothelial leukocyte adhesion and transmigration via NF-kappaB dependent up-regulation of IL-8 and MCP-1. Kidney Int 2002;62:846-856

23. Obrig TG, Louise CB, Lingwood CA, et al. Endothelial heterogeneity in Shiga toxin receptors and responses. J Biol Chem 1993;268:15484-15488

24. Friedrich AlexanderÂ W, Zhang W, Bielaszewska M, et al. Prevalence, virulence profiles, and clinical significance of Shiga toxin negative variants of enterohemorrhagic Escherichia coli O157 Infection in Humans. Clinical Infectious Diseases 2007;45:39-45

25. Bielaszewska M, Karch H. Consequences of enterohaemorrhagic Escherichia coli infection for the vascular endothelium. Thromb Haemost 2005;94:312-318

26. Friedrich AW, Lu S, Bielaszewska M, et al. Cytolethal Distending Toxin in Escherichia coli O157:H7: Spectrum of Conservation, Structure, and Endothelial Toxicity. J Clin Microbiol 2006;44:1844-1846

27. Bielaszewska M, Sinha B, Kuczius T, Karch H. Cytolethal Distending Toxin from Shiga Toxin-Producing Escherichia coli O157 Causes Irreversible G2/M Arrest, Inhibition of Proliferation, and Death of Human Endothelial Cells. Infect Immun 2005;73:552-562

28. Aldick T, Bielaszewska M, Zhang W, et al. Hemolysin from Shiga toxin-negative Escherichia coli O26 strains injures microvascular endothelium. Microbes Infect 2007;9:282-290

29. Paton AW, Srimanote P, Talbot UM, Wang H, Paton JC. A new family of potent AB(5) cytotoxins produced by Shiga toxigenic Escherichia coli. J Exp Med 2004;200:35-46

30. Paton AW, Beddoe T, Thorpe CM, et al. AB5 subtilase cytotoxin inactivates the endoplasmic reticulum chaperone BiP. Nature 2006;443:548-552

31. Hu CC, Dougan SK, Winter SV, et al. Subtilase cytotoxin cleaves newly synthesized BiP and blocks antibody secretion in B lymphocytes. J Exp Med 2009;206:2429-2440

32. McKee ML, O'Brien AD. Investigation of enterohemorrhagic Escherichia coli O157:H7 adherence characteristics and invasion potential reveals a new attachment pattern shared by intestinal E. coli. Infect Immun 1995;63:2070-2074

33. Kaper JB, Nataro JP, Mobley HL. Pathogenic Escherichia coli. Nat Rev Microbiol 2004;2:123-140

34. Malyukova I, Murray KF, Zhu C, et al. Macropinocytosis in Shiga toxin 1 uptake by human intestinal epithelial cells and transcellular transcytosis. Am J Physiol Gastrointest Liver Physiol 2009;296:G78-92

35. Phillips AD, Navabpour S, Hicks S, et al. Enterohaemorrhagic Escherichia coli O157:H7 target Peyer's patches in humans and cause attaching/effacing lesions in both human and bovine intestine. Gut 2000;47:377-381

36. Chong Y, Fitzhenry R, Heuschkel R, et al. Human intestinal tissue tropism in Escherichia coli O157 : H7--initial colonization of terminal ileum and Peyer's patches and minimal colonic adhesion ex vivo. Microbiology 2007;153:794-802

37. Nataro JP, Kaper JB. Diarrheagenic Escherichia coli. Clin Microbiol Rev 1998;11:142-201

38. Pacheco AR, Sperandio V. Inter-kingdom signaling: chemical language between bacteria and host. Curr Opin Microbiol 2009;12:192-198

39. Hughes DT, Clarke MB, Yamamoto K, Rasko DA, Sperandio V. The QseC adrenergic signaling cascade in Enterohemorrhagic E. coli (EHEC). PLoS Pathog 2009;5:e1000553

40. Dytoc MT, Ismaili A, Philpott DJ, et al. Distinct binding properties of eaeA-negative verocytotoxin-producing Escherichia coli of serotype O113:H21. Infect Immun 1994;62:3494-3505

41. Vidal M, Prado V, Whitlock GC, et al. Subtractive hybridization and identification of putative adhesins in a Shiga toxin-producing eae-negative Escherichia coli. Microbiology 2008;154:3639-3648

42. Bardiau M, Labrozzo S, Mainil JG. Putative adhesins of enteropathogenic and enterohemorrhagic Escherichia coli of serogroup O26 isolated from humans and cattle. J Clin Microbiol 2009;47:2090-2096

43. Mundy R, Jenkins C, Yu J, Smith H, Frankel G. Distribution of espI among clinical enterohaemorrhagic and enteropathogenic Escherichia coli isolates. J Med Microbiol 2004;53:1145-1149

44. Xicohtencatl-Cortes J, Monteiro-Neto V, Saldana Z, et al. The type 4 pili of enterohemorrhagic Escherichia coli O157:H7 are multipurpose structures with pathogenic attributes. J Bacteriol 2009;191:411-421

45. Fontaine A, Arondel J, Sansonetti PJ. Role of Shiga toxin in the pathogenesis of bacillary dysentery, studied by using a Tox- mutant of Shigella dysenteriae 1. Infect Immun 1988;56:3099-3109

46. Schuller S, Heuschkel R, Torrente F, Kaper JB, Phillips AD. Shiga toxin binding in normal and inflamed human intestinal mucosa. Microbes Infect 2007;9:35-39

47. Smith WE, Kane AV, Campbell ST, et al. Shiga toxin 1 triggers a ribotoxic stress response leading to p38 and JNK activation and induction of apoptosis in intestinal epithelial cells. Infect Immun 2003;71:1497-1504

48. Schuller S, Frankel G, Phillips AD. Interaction of Shiga toxin from Escherichia coli with human intestinal epithelial cell lines and explants: Stx2 induces epithelial damage in organ culture. Cell Microbiol 2004;6:289-301

49. Kashiwamura M, Kurohane K, Tanikawa T, et al. Shiga toxin kills epithelial cells isolated from distal but not proximal part of mouse colon. Biol Pharm Bull 2009;32:1614-1617

50. Hurley BP, Jacewicz M, Thorpe CM, et al. Shiga toxins 1 and 2 translocate differently across polarized intestinal epithelial cells. Infect Immun 1999;67:6670-6677

51. Hurley BP, Thorpe CM, Acheson DW. Shiga toxin translocation across intestinal epithelial cells is enhanced by neutrophil transmigration. Infect Immun 2001;69:6148-6155

52. de Sablet T, Chassard C, Bernalier-Donadille A, et al. Human microbiota-secreted factors inhibit Shiga toxin synthesis by enterohemorrhagic Escherichia coli O157:H7. Infect Immun 2009;77:783-790

53. Bielaszewska M, Friedrich AW, Aldick T, Schurk-Bulgrin R, Karch H. Shiga toxin activatable by intestinal mucus in Escherichia coli isolated from humans: predictor for a severe clinical outcome. Clin Infect Dis 2006;43:1160-1167

54. Cherla RP, Lee SY, Tesh VL. Shiga toxins and apoptosis. FEMS Microbiol Lett 2003;228:159-166

55. Byres E, Paton AW, Paton JC, et al. Incorporation of a non-human glycan mediates human susceptibility to a bacterial toxin. Nature 2008;456:648-652

56. Lofling JC, Paton AW, Varki NM, Paton JC, Varki A. A dietary non-human sialic acid may facilitate hemolytic-uremic syndrome. Kidney Int 2009;76:140-144

57. Thorpe CM, Hurley BP, Lincicome LL, et al. Shiga toxins stimulate secretion of interleukin-8 from intestinal epithelial cells. Infect Immun 1999;67:5985-5993

58. Thorpe CM, Smith WE, Hurley BP, Acheson DW. Shiga toxins induce, superinduce, and stabilize a variety of C-X-C chemokine mRNAs in intestinal epithelial cells, resulting in increased chemokine expression. Infect Immun 2001;69:6140-6147

59. Bellmeyer A, Cotton C, Kanteti R, et al. Enterohemorrhagic Escherichia coli suppresses inflammatory response to cytokines and its own toxin. Am J Physiol Gastrointest Liver Physiol 2009;297:G576-581

60. van de Kar NC, Monnens LA, Karmali MA, van Hinsbergh VW. Tumor necrosis factor and interleukin-1 induce expression of the verocytotoxin receptor globotriaosylceramide on human endothelial cells: implications for the pathogenesis of the hemolytic uremic syndrome. Blood 1992;80:2755-2764

61. Karpman D, Connell H, Svensson M, et al. The role of lipopolysaccharide and Shiga-like toxin in a mouse model of Escherichia coli O157:H7 infection. J Infect Dis 1997;175:611-620

62. Calderon Toledo C, Rogers TJ, Svensson M, et al. Shiga toxin-mediated disease in MyD88-deficient mice infected with Escherichia coli O157:H7. Am J Pathol 2008;173:1428-1439

63. Iimura M, Gallo RL, Hase K, et al. Cathelicidin mediates innate intestinal defense against colonization with epithelial adherent bacterial pathogens. J Immunol 2005;174:4901-4907

64. Ståhl AL, Sartz L, Nelsson A, Békássy ZD, Karpman D. Shiga toxin and lipopolysaccharide induce platelet-leukocyte aggregates and tissue factor release, a thrombotic mechanism in hemolytic uremic syndrome. PLoS One 2009;4:e6990

65. Ståhl AL, Svensson M, Mörgelin M, et al. Lipopolysaccharide from enterohemorrhagic Escherichia coli binds to platelets through TLR4 and CD62 and is detected on circulating platelets in patients with hemolytic uremic syndrome. Blood 2006;108:167-176

66. Tazzari PL, Ricci F, Carnicelli D, et al. Flow cytometry detection of Shiga toxins in the blood from children with hemolytic uremic syndrome. Cytometry B Clin Cytom 2004;61:40-44

67. Cooling LL, Walker KE, Gille T, Koerner TA. Shiga toxin binds human platelets via globotriaosylceramide (Pk antigen) and a novel platelet glycosphingolipid. Infect Immun 1998;66:4355-4366

68. te Loo DM, Monnens LA, van Der Velden TJ, et al. Binding and transfer of verocytotoxin by polymorphonuclear leukocytes in hemolytic uremic syndrome. Blood 2000;95:3396-3402

69. van Setten PA, Monnens LA, Verstraten RG, van den Heuvel LP, van Hinsbergh VW. Effects of verocytotoxin-1 on nonadherent human monocytes: binding characteristics, protein synthesis, and induction of cytokine release. Blood 1996;88:174-183

70. Obrig TG, Moran TP, Colinas RJ. Ribonuclease activity associated with the 60S ribosome-inactivating proteins ricin A, phytolaccin and Shiga toxin. Biochem Biophys Res Commun 1985;130:879-884

71. Liu J, Akahoshi T, Sasahana T, et al. Inhibition of neutrophil apoptosis by verotoxin 2 derived from Escherichia coli O157:H7. Infect Immun 1999;67:6203-6205

72. Cohen A, Madrid-Marina V, Estrov Z, et al. Expression of glycolipid receptors to Shiga-like toxin on human B lymphocytes: a mechanism for the failure of long-lived antibody response to dysenteric disease. Int Immunol 1990;2:1-8

73. Brigotti M, Carnicelli D, Ravanelli E, et al. Interactions between Shiga toxins and human polymorphonuclear leukocytes. J Leukoc Biol 2008;84:1019-1027

74. Lee SY, Cherla RP, Tesh VL. Simultaneous induction of apoptotic and survival signaling pathways in macrophage-like THP-1 cells by Shiga toxin 1. Infect Immun 2007;75:1291-1302

75. Walters MD, Matthei IU, Kay R, Dillon MJ, Barratt TM. The polymorphonuclear leucocyte count in childhood haemolytic uraemic syndrome. Pediatr Nephrol 1989;3:130-134

76. Fitzpatrick MM, Shah V, Filler G, Dillon MJ, Barratt TM. Neutrophil activation in the haemolytic uraemic syndrome: free and complexed elastase in plasma. Pediatr Nephrol 1992;6:50-53

77. Fernandez GC, Gomez SA, Ramos MV, et al. The functional state of neutrophils correlates with the severity of renal dysfunction in children with hemolytic uremic syndrome. Pediatr Res 2007;61:123-128

78. Fernandez GC, Lopez MF, Gomez SA, et al. Relevance of neutrophils in the murine model of haemolytic uraemic syndrome: mechanisms involved in Shiga toxin type 2-induced neutrophilia. Clin Exp Immunol 2006;146:76-84

79. Szabady RL, Lokuta MA, Walters KB, Huttenlocher A, Welch RA. Modulation of neutrophil function by a secreted mucinase of Escherichia coli O157:H7. PLoS Pathog 2009;5:e1000320

80. Inward CD, Howie AJ, Fitzpatrick MM, et al. Renal histopathology in fatal cases of diarrhoea-associated haemolytic uraemic syndrome. British Association for Paediatric Nephrology. Pediatr Nephrol 1997;11:556-559

81. Exeni RA, Fernandez GC, Palermo MS. Role of polymorphonuclear leukocytes in the pathophysiology of typical hemolytic uremic syndrome. Scient World J 2007;7:1155-1164

82. Geelen JM, van der Velden TJ, van den Heuvel LP, Monnens LA. Interactions of Shiga-like toxin with human peripheral blood monocytes. Pediatr Nephrol 2007;22:1181-1187

83. Sakiri R, Ramegowda B, Tesh VL. Shiga toxin type 1 activates tumor necrosis factor-alpha gene transcription and nuclear translocation of the transcriptional activators nuclear factor-kappaB and activator protein-1. Blood 1998;92:558-566

84. Guessous F, Marcinkiewicz M, Polanowska-Grabowska R, et al. Shiga toxin 2 and lipopolysaccharide cause monocytic THP-1 cells to release factors which activate platelet function. Thromb Haemost 2005;94:1019-1027

85. Murata K, Higuchi T, Takada K, et al. Verotoxin-1 stimulation of macrophage-like THP-1 cells up-regulates tissue factor expression through activation of c-Yes tyrosine kinase: Possible signal transduction in tissue factor up-regulation. Biochim Biophys Acta 2006;1762:835-843

86. Karpman D, Manea M, Vaziri-Sani F, Stahl AL, Kristoffersson AC. Platelet activation in hemolytic uremic syndrome. Semin Thromb Hemost 2006;32:128-145

87. Karpman D, Papadopoulou D, Nilsson K, et al. Platelet activation by Shiga toxin and circulatory factors as a pathogenetic mechanism in the hemolytic uremic syndrome. Blood 2001;97:3100-3108

88. Ghosh SA, Polanowska-Grabowska RK, Fujii J, Obrig T, Gear AR. Shiga toxin binds to activated platelets. J Thromb Haemost 2004;2:499-506

89. Keepers TR, Psotka MA, Gross LK, Obrig TG. A murine model of HUS: Shiga toxin with lipopolysaccharide mimics the renal damage and physiologic response of human disease. J Am Soc Nephrol 2006;17:3404-3414

90. Kamitsuji H, Nonami K, Murakami T, et al. Elevated tissue factor circulating levels in children with hemolytic uremic syndrome caused by verotoxin-producing E. coli. Clin Nephrol 2000;53:319-324

91. Ishii H, Takada K, Higuchi T, Sugiyama J. Verotoxin-1 induces tissue factor expression in human umbilical vein endothelial cells through activation of NF-kappaB/Rel and AP-1. Thromb Haemost 2000;84:712-721

92. Nestoridi E, Tsukurov O, Kushak RI, Ingelfinger JR, Grabowski EF. Shiga toxin enhances functional tissue factor on human glomerular endothelial cells: implications for the pathophysiology of hemolytic uremic syndrome. J Thromb Haemost 2005;3:752-762

93. Nestoridi E, Kushak RI, Tsukurov O, Grabowski EF, Ingelfinger JR. Role of the renin angiotensin system in TNF-alpha and Shiga-toxin-induced tissue factor expression. Pediatr Nephrol 2008;23:221-231

94. Sugatani J, Igarashi T, Munakata M, et al. Activation of coagulation in C57BL/6 mice given verotoxin 2 (VT2) and the effect of co-administration of LPS with VT2. Thromb Res 2000;100:61-72

95. Raife T, Friedman KD, Fenwick B. Lepirudin prevents lethal effects of Shiga toxin in a canine model. Thromb Haemost 2004;92:387-393

96. Taylor FB, Jr., Tesh VL, DeBault L, et al. Characterization of the baboon responses to Shiga-like toxin: descriptive study of a new primate model of toxic responses to Stx-1. Am J Pathol 1999;154:1285-1299

97. Turi S, Nemeth I, Vargha I, Matkovics B. Oxidative damage of red blood cells in haemolytic uraemic syndrome. Pediatr Nephrol 1994;8:26-29

98. Bitzan M, Bickford BB, Foster GH. Verotoxin (Shiga toxin) sensitizes renal epithelial cells to increased heme toxicity: possible implications for the hemolytic uremic syndrome. J Am Soc Nephrol 2004;15:2334-2343

99. Gallo EG, Gianantonio CA. Extrarenal involvement in diarrhoea-associated haemolytic-uraemic syndrome. Pediatr Nephrol 1995;9:117-119

100. Hughes AK, Ergonul Z, Stricklett PK, Kohan DE. Molecular basis for high renal cell sensitivity to the cytotoxic effects of Shigatoxin-1: upregulation of globotriaosylceramide expression. J Am Soc Nephrol 2002;13:2239-2245

101. Okuda T, Tokuda N, Numata S, et al. Targeted disruption of Gb3/CD77 synthase gene resulted in the complete deletion of globo-series glycosphingolipids and loss of sensitivity to verotoxins. J Biol Chem 2006;281:10230-10235

102. Ergonul Z, Clayton F, Fogo AB, Kohan DE. Shigatoxin-1 binding and receptor expression in human kidneys do not change with age. Pediatr Nephrol 2003;18:246-253

103. Karpman D, Hakansson A, Perez MT, et al. Apoptosis of renal cortical cells in the hemolytic-uremic syndrome: in vivo and in vitro studies. Infect Immun 1998;66:636-644

104. Kaneko K, Kiyokawa N, Ohtomo Y, et al. Apoptosis of renal tubular cells in Shiga-toxin-mediated hemolytic uremic syndrome. Nephron 2001;87:182-185

105. van Setten PA, van Hinsbergh VW, van der Velden TJ, et al. Effects of TNF alpha on verocytotoxin cytotoxicity in purified human glomerular microvascular endothelial cells. Kidney Int 1997;51:1245-1256

106. Pijpers AH, van Setten PA, van den Heuvel LP, et al. Verocytotoxin-induced apoptosis of human microvascular endothelial cells. J Am Soc Nephrol 2001;12:767-778

107. Williams JM, Boyd B, Nutikka A, et al. A comparison of the effects of verocytotoxin-1 on primary human renal cell cultures. Toxicol Lett 1999;105:47-57

108. Hughes AK, Stricklett PK, Schmid D, Kohan DE. Cytotoxic effect of Shiga toxin-1 on human glomerular epithelial cells. Kidney Int 2000;57:2350-2359

109. Hughes AK, Stricklett PK, Kohan DE. Shiga toxin-1 regulation of cytokine production by human glomerular epithelial cells. Nephron 2001;88:14-23

110. Lee JE, Kim JS, Choi IH, et al. Cytokine expression in the renal tubular epithelial cells stimulated by Shiga toxin 2 of Escherichia coli O157:H7. Ren Fail 2002;24:567-575

111. Zanchi C, Zoja C, Morigi M, et al. Fractalkine and CX3CR1 mediate leukocyte capture by endothelium in response to Shiga toxin. J Immunol 2008;181:1460-1469

112. Ramos MV, Fernandez GC, Patey N, et al. Involvement of the fractalkine pathway in the pathogenesis of childhood hemolytic uremic syndrome. Blood 2007;109:2438-2445

113. Trachtman H, Christen E, Cnaan A, et al. Urinary neutrophil gelatinase-associated lipocalcin in D+HUS: a novel marker of renal injury. Pediatr Nephrol 2006;21:989-994

114. Ake JA, Jelacic S, Ciol MA, et al. Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion. Pediatrics 2005;115:e673-680

115. Wadolkowski EA, Sung LM, Burris JA, Samuel JE, O'Brien AD. Acute renal tubular necrosis and death of mice orally infected with Escherichia coli strains that produce Shiga-like toxin type II. Infect Immun 1990;58:3959-3965

116. Zotta E, Lago N, Ochoa F, Repetto HA, Ibarra C. Development of an experimental hemolytic uremic syndrome in rats. Pediatr Nephrol 2008;23:559-567

117. Silberstein C, Pistone Creydt V, Gerhardt E, Nunez P, Ibarra C. Inhibition of water absorption in human proximal tubular epithelial cells in response to Shiga toxin-2. Pediatr Nephrol 2008;23:1981-1990

118. Sugatani J, Komiyama N, Mochizuki T, et al. Urinary concentrating defect in rats given Shiga toxin: elevation in urinary AQP2 level associated with polyuria. Life Sci 2002;71:171-189

119. Psotka MA, Obata F, Kolling GL, et al. Shiga toxin 2 targets the murine renal collecting duct epithelium. Infect Immun 2009;77:959-969

120. Nestoridi E, Kushak RI, Duguerre D, Grabowski EF, Ingelfinger JR. Up-regulation of tissue factor activity on human proximal tubular epithelial cells in response to Shiga toxin. Kidney Int 2005;67:2254-2266

121. Morigi M, Buelli S, Zanchi C, et al. Shigatoxin-induced endothelin-1 expression in cultured podocytes autocrinally mediates actin remodeling. Am J Pathol 2006;169:1965-1975

122. Bitzan MM, Wang Y, Lin J, Marsden PA. Verotoxin and ricin have novel effects on preproendothelin-1 expression but fail to modify nitric oxide synthase (ecNOS) expression and NO production in vascular endothelium. J Clin Invest 1998;101:372-382

123. Shigematsu H, Dikman SH, Churg J, Grishman E, Duffy JL. Mesangial involvement in hemolytic-uremic syndrome. A light and electron microscopic study. Am J Pathol 1976;85:349-362

124. Warnier M, Romer W, Geelen J, et al. Trafficking of Shiga toxin/Shiga-like toxin-1 in human glomerular microvascular endothelial cells and human mesangial cells. Kidney Int 2006;70:2085-2091

125. Simon M, Cleary TG, Hernandez JD, Abboud HE. Shiga toxin 1 elicits diverse biologic responses in mesangial cells. Kidney Int 1998;54:1117-1127

126. Te Loo DM, Monnens L, van der Velden T, et al. Shiga toxin-1 affects nitric oxide production by human glomerular endothelial and mesangial cells. Pediatr Nephrol 2006;21:1815-1823

127. Van Setten PA, van Hinsbergh VW, Van den Heuvel LP, et al. Verocytotoxin inhibits mitogenesis and protein synthesis in purified human glomerular mesangial cells without affecting cell viability: evidence for two distinct mechanisms. J Am Soc Nephrol 1997;8:1877-1888

128. Obata F, Tohyama K, Bonev AD, et al. Shiga toxin 2 affects the central nervous system through receptor globotriaosylceramide localized to neurons. J Infect Dis 2008;198:1398-1406

129. Fujii J, Wood K, Matsuda F, et al. Shiga toxin 2 causes apoptosis in human brain microvascular endothelial cells via C/EBP homologous protein. Infect Immun 2008;76:3679-3689

130. Ergonul Z, Hughes AK, Kohan DE. Induction of apoptosis of human brain microvascular endothelial cells by shiga toxin 1. J Infect Dis 2003;187:154-158

131. Stricklett PK, Hughes AK, Ergonul Z, Kohan DE. Molecular basis for up-regulation by inflammatory cytokines of Shiga toxin 1 cytotoxicity and globotriaosylceramide expression. J Infect Dis 2002;186:976-982

132. Goldstein J, Loidl CF, Creydt VP, Boccoli J, Ibarra C. Intracerebroventricular administration of Shiga toxin type 2 induces striatal neuronal death and glial alterations: an ultrastructural study. Brain Res 2007;1161:106-115

133. Boccoli J, Loidl CF, Lopez-Costa JJ, et al. Intracerebroventricular administration of Shiga toxin type 2 altered the expression levels of neuronal nitric oxide synthase and glial fibrillary acidic protein in rat brains. Brain Res 2008;1230:320-333

134. Eisenhauer PB, Jacewicz MS, Conn KJ, et al. Escherichia coli Shiga toxin 1 and TNF-alpha induce cytokine release by human cerebral microvascular endothelial cells. Microb Pathog 2004;36:189-196

135. Manuelian T, Hellwage J, Meri S, et al. Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J Clin Invest 2003;111:1181-1190

136. Stahl AL, Vaziri-Sani F, Heinen S, et al. Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation. Blood 2008;111:5307-5315

137. Thurman JM, Marians R, Emlen W, et al. Alternative Pathway of Complement in Children with Diarrhea-Associated Hemolytic Uremic Syndrome. Clin J Am Soc Nephrol 2009

138. Orth D, Khan AB, Naim A, et al. Shiga Toxin Activates Complement and Binds Factor H: Evidence for an Active Role of Complement in Hemolytic Uremic Syndrome. J Immunol 2009;182:6394-6400

139. Hughes DT, Sperandio V. Inter-kingdom signalling: communication between bacteria and their hosts. Nat Rev Microbiol 2008;6:111-120

140. Chandler WL, Jelacic S, Boster DR, et al. Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome. N Engl J Med 2002;346:23-32

141. Manea M, Kristoffersson A, Schneppenheim R, et al. Podocytes express ADAMTS13 in normal renal cortex and in patients with thrombotic thrombocytopenic purpura. Br J Haematol 2007;138:651-662

Figure legend

Figure 1: Tissue factor expression in the renal cortex of a child with *E. coli* O157:H7-associated HUS

Kidney tissue from a 14 year-old boy with *E. coli* O157-associated HUS (A) and from an adult control whose kidney was removed due to renal cancer, showing an area unaffected by cancer (B).[141] Tissue factor was detected by immunohistochemistry using monoclonal mouse anti-human tissue factor antibody (0.7µg/ml, American Diagnostica Inc, Stamford, CT, USA). Signal was detected using an EnVision System goat-α-mouse:HRP (Dako Cytomation, Glostrup, Denmark) secondary antibody as described.[141] Tissue factor was detected in glomerular capillaries (arrow) and proximal tubular cells (asterix) as well as in the Bowman´s capsule. Mouse IgG1 (Dako Cytomation) was used as the isotype control and did not show staining (not shown). The study was approved by the Ethics Committee of the Medical Faculty at Lund University and biopsies were taken with the informed consent of the patient and control.



Figure 1